Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + SCT800 for Hemophilia A with Inhibitors
NCT05888870Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of daratumumab in hemophilia A (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Success rate of ITI at 12 months and Success rate and partial success rate of ITI at 3 months. Started Nov 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05888870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05888870.